Defense World
24 Jan 2026, 10:22 UTC · 41w ago
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
Impact · against what's priced in
The CEO's sale of 75,000 shares is a negligible event. The divestment represents only ~6.8% of his total position, suggesting it is likely for personal liquidity rather than a signal of fundamental deterioration.
- FOLD−0.05
No priced-in read yet
- In context
CEO Bradley Campbell sold 75,000 shares at $14.31, but retains over 1 million shares, indicating his overall commitment to the company remains largely intact.
Read from the article alone
Search tags
